The estimated Net Worth of Brian Elsbernd is at least $3.19 Milión dollars as of 27 March 2024. Mr. Elsbernd owns over 25,000 units of Catalyst Pharmaceuticals Inc stock worth over $2,421,466 and over the last 5 years he sold CPRX stock worth over $411,000. In addition, he makes $353,274 as Chief Compliance Officer a Chief Legal Officer at Catalyst Pharmaceuticals Inc.
Brian has made over 9 trades of the Catalyst Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 25,000 units of CPRX stock worth $411,000 on 27 March 2024.
The largest trade he's ever made was exercising 105,000 units of Catalyst Pharmaceuticals Inc stock on 11 November 2022 worth over $152,250. On average, Brian trades about 16,667 units every 79 days since 2019. As of 27 March 2024 he still owns at least 124,433 units of Catalyst Pharmaceuticals Inc stock.
You can see the complete history of Mr. Elsbernd stock trades at the bottom of the page.
Brian D. Elsbernd J.D. serves as Chief Compliance Officer, Chief Legal Officer of the Company. Prior to joining Catalyst, Mr. Elsbernd was, from 2004 until February 2016, employed in various capacities with Mallinckrodt Pharmaceuticals and its predecessors, including as Senior Director of U.S. Healthcare Compliance. At Mallinckrodt, he was involved in the building of their formal compliance program including providing leadership and vision on ethics and business conduct while also managing multiple other legal and business functions. Before joining Mallinckrodt, Mr. Elsbernd was an associate at Proskauer Rose LLP, within its Health Care practice group, representing health care providers nationwide in matters pertaining to regulatory and administrative law, transactional matters, litigation, and reimbursement issues. Mr. Elsbernd holds a Bachelor of Arts degree in history from the University of Illinois-Urbana and a law degree from the Saint Louis University School of Law.
As the Chief Compliance Officer a Chief Legal Officer of Catalyst Pharmaceuticals Inc, the total compensation of Brian Elsbernd at Catalyst Pharmaceuticals Inc is $353,274. There are 9 executives at Catalyst Pharmaceuticals Inc getting paid more, with Patrick McEnany having the highest compensation of $3,371,560.
Brian Elsbernd is 56, he's been the Chief Compliance Officer a Chief Legal Officer of Catalyst Pharmaceuticals Inc since 2019. There are 11 older and 4 younger executives at Catalyst Pharmaceuticals Inc. The oldest executive at Catalyst Pharmaceuticals Inc is Charles O'Keeffe, 80, who is the Lead Independent Director.
Brian's mailing address filed with the SEC is 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES, FL, 33134.
Over the last 18 years, insiders at Catalyst Pharmaceuticals Inc have traded over $35,595,986 worth of Catalyst Pharmaceuticals Inc stock and bought 7,401,098 units worth $7,307,159 . The most active insiders traders include Pharmaceutical Inc Biomarin, Patrick J Mcenany a Steve Miller. On average, Catalyst Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $1,097,019. The most recent stock trade was executed by David S Tierney on 21 August 2024, trading 15,000 units of CPRX stock currently worth $60,150.
catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso
Catalyst Pharmaceuticals Inc executives and other stock owners filed with the SEC include: